Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX Stock-Based Comp

Stock-Based Comp at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$4.82M+79.5%

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost.

The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's stock-based comp?
BioCryst Pharmaceuticals (BCRX) reported stock-based comp of $1.21M in Q4 2025.
How has BioCryst Pharmaceuticals's stock-based comp changed year-over-year?
BioCryst Pharmaceuticals's stock-based comp increased by 74.0% year-over-year, from $695K to $1.21M.
What is the long-term trend for BioCryst Pharmaceuticals's stock-based comp?
Over 2 years (2023 to 2025), BioCryst Pharmaceuticals's stock-based comp has grown at a 35.7% compound annual growth rate (CAGR), from $2.63M to $4.84M.
What does stock-based comp mean?
Quantifies the total expense recognized for equity-based compensation provided to employees and directors. This metric reflects the cost of aligning employee incentives with shareholder interests through stock awards. It is a critical component of non-cash operating expenses and impacts overall profitability.